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Abstract
Background: Distalgesic, the prescription-only analgesic compound of paracetamol (325 mg) and
dextropropoxyphene (32.5 mg) known as co-proxamol in the UK, was withdrawn from the Irish market as of
January 2006. This study aimed to evaluate the impact of the withdrawal of distalgesic in terms of intentional drug
overdose (IDO) presentations to hospital emergency departments (EDs) nationally.
Methods: A total of 42,849 IDO presentations to 37 of the 40 hospitals EDs operating in Ireland in 2003-2008 were
recorded according to standardised procedures. Data on sales of paracetamol-containing drugs to retail pharmacies
for the period 1998-2008 were obtained from IMS Health.
Results: The withdrawal of distalgesic from the Irish market resulted in an immediate reduction in sales to retail
pharmacies from 40 million tablets in 2005 to 500,000 tablets in 2006 while there was a 48% increase in sales of
other prescription compound analgesics. The rate of IDO presentations to hospital involving distalgesic in 2006-
2008 was 84% lower than in the three years before it was withdrawn (10.0 per 100,000). There was a 44% increase
in the rate of IDO presentations involving other prescription compound analgesics but the magnitude of this rate
increase was five times smaller than the magnitude of the decrease in distalgesic-related IDO presentations. There
was a decreasing trend in the rate of presentations involving any paracetamol-containing drug that began in the
years before the distalgesic withdrawal.
Conclusions: The withdrawal of distalgesic has had positive benefits in terms of IDO presentations to hospital in
Ireland and provides evidence supporting the restriction of availability of means as a prevention strategy for
suicidal behaviour.
Background
Distalgesic (known as co-proxamol in the UK) is a pre-
scription-only analgesic compound of paracetamol (325
mg) and dextropropoxyphene (32.5 mg). Evidence of the
dangers of distalgesic in overdose began with a case-ser-
ies study in Northern Ireland over 30 years ago [1] and
culminated with a study that showed that the drug was
the second most commonly used drug in overdose sui-
cides in England and Wales, accounting for 5% of all
suicides and with a higher risk of fatal outcome in over-
dose acts than other commonly used medicines [2].
Death from distalgesic overdose may occur rapidly, even
with a relatively low dose, and lethality is increased by
use of alcohol and other central nervous system depres-
sants. As a consequence, the majority of overdose deaths
occur before hospital treatment can be received [3].
After extensive review of the risks and benefit, the drug
was withdrawn from the UK market over a three-year
period, 2005-2007. Distalgesic was withdrawn from the
Irish market as of January 2006.
The efficacy of various suicide prevention strategies to
reduce the risk of suicide involving distalgesic has been
evaluated, including educational strategies for doctors,
restricting the number of prescribed tablets, restrictions
on prescribing and complete withdrawal [3]. So far,
restricting availability of distalgesic has produced posi-
tive results in the UK, Scandinavia and Australia [4-8].* Correspondence: dpaulcorcoran@gmail.com1National Suicide Research Foundation, 1 Perrott Avenue, College Road,
Cork, Ireland
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This study aimed to evaluate the impact of the with-
drawal of distalgesic from the Irish market in terms of
intentional drug overdose (IDO) presentations to hospi-
tal emergency departments (EDs) nationally. Specifically,
we compared the rate of presentations to hospital of
IDO acts involving distalgesic before (2003-2005) and
after (2006-2008) its withdrawal, tested for evidence of
substitution whereby there was a change in the rate of
overdose presentations involving other paracetamol-
containing drugs and examined whether there was a
change in the number of tablets taken in overdose
presentations involving distalgesic. We also examined
changes in sales to retail pharmacies of paracetamol-
containing analgesics.
Methods
Data sources
The National Registry of Deliberate Self Harm collects
data from all hospital emergency departments (EDs) in
Ireland using an internationally-recognised definition
that includes all non-fatal intentional drug overdose
(IDO) acts [9]. Registry data are collected by trained
data registration officers who operate independently of
the hospitals and follow standard operating procedures.
Quality control measures include regular team meetings
to reinforce the standardised application of case-defini-
tion and ascertainment criteria as well as cross-checking
exercises which have shown high levels of agreement
and reliability across registration officers. A minimal
dataset is collected, described in detail in the Registry’s
annual reports [10]. The dataset includes the age, gender
and area of residence of the patient, data regarding the
nature of the self-harming behaviour and whether the
patient was hospitalised. If multiple IDO presentations
are made by the same individual, all are recorded by the
Registry. Ethical approval for the Registry was granted
by the National Ethics Committee of the Faculty of
Public Health Medicine as well as by local ethics
committees.
Population data from the 2006 national census and
annual population estimates for 2003, 2004, 2005, 2007
and 2008 (disaggregated by sex and age group) were
obtained from the website of the Irish Central Statistics
Office (CSO; http://www.cso.ie/). IMS Health supplied
data on wholesale sales of paracetamol-containing drugs
to retail pharmacies in Ireland for the period 1998-2008.
Data analysis
Of the 40 hospital EDs operating in Ireland in 2003-
2008, the Registry obtained data from 37 hospitals in
2003, 38 hospitals in 2004-2005 and all 40 hospitals in
2006-2008. Statistical analysis was limited to the data
collected from the 37 hospitals that contributed to the
Registry for the complete study period (2003-2008).
These hospitals accounted for 86.5% of all Registry-
recorded IDO presentations in 2006-2008. This propor-
tion was used to derive a weighting (100/86.5 = 1.16)
that was applied to the data of the 37 hospitals for all
study years and these weighted data were used to calcu-
late national presentation rates. Total, male and female
rates of IDO presentations to hospital per 100,000 popu-
lation were age-standardised using the European stan-
dard population [11]. Five year age groups (0-4, 5-9, ...,
80-84 and 85+) were used for the age-standardisation
but when the data were more limited broader age
groups were used (0-14, 15-34, 35-54, 55+). Assuming
that the number of presentations (x) followed a Poisson
distribution, 95% confidence intervals (CIs) for the rates
were calculated using the Normal approximation, i.e.
confidence interval = (x +/- 2*√x) * 100,000/population.
Data analysis was carried out relating to all IDO pre-
sentations, presentations involving any paracetamol-con-
taining drug and presentations involving distalgesic. We
also examined presentations involving the other com-
mon, paracetamol compound, prescription-only, moder-
ate-severe painkillers that were available in the country
across the study period (Kapake, Paramol, Solpadol,
Syndol and Tylex; referred to as ‘other prescription
compound analgesics’ in the paper) and presentations
involving solpadeine, by far the most common over-the-
counter paracetamol compound analgesic available only
from pharmacies.
Chi-square tests were used to assess whether the pro-
portion of IDO presentations to hospital involving dis-
talgesic varied by sex, age and year. Poisson regression
analysis was used to assess rate differences by sex and
year and changes between the three pre-withdrawal
years and the three post-withdrawal years collectively
and separately (i.e. 2003-2005 vs. 2006-2008 and 2003-
2005 vs. 2006, 2007, 2008). The number of distalgesic
tablets taken was recorded in 84% of the IDO presenta-
tions involving the drug. Because of its skewed distribu-
tion, the number of tablets was summarised by the
median and interquartile range. The non-parametric
Mann-Whitney test was used to assess variation in the
number of tablets taken between two groups and the
Kruskal-Wallis test was used to compare more than two
groups.
The statistical analysis was carried out using SPSS
version 16.0 (SPSS Inc., Illinois, USA) except for the
Poisson regression analyses, which were carried out
using Stata version 6.0 (StataCorp, Texas, USA).
Results
In 2003-2008, there were 42,849 recorded intentional
drug overdose (IDO) presentations to the 37 hospital
EDs that contributed fully to the Registry during these
six years (annual mean (range): 7,142 (6,642-7,692)).
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Women accounted for 61.2% of all IDO presentations, a
proportion that did not vary by year (Chi-square = 5.33,
df = 5, p = 0.139). In 2,050 (4.8%) of the IDO presenta-
tions, it was not known what drugs were taken. The
total, male and female annual rates of IDO presentations
to hospital EDs were 188.4 (95% CI = 186.6-190.1),
143.5 (95% CI = 141.3-145.7) and 234.3 (95% CI =
231.5-237.0) per 100,000 population, respectively.
Female sex was associated with a 60% higher rate of
IDO presentations after adjustment for age (IRR = 1.60,
95% CI = 1.57-1.63). At least one paracetamol-contain-
ing drug was involved in 13,066 (30.5%) of the IDO pre-
sentations. The total, male and female annual rates of
IDO presentations to hospital involving paracetamol
were 57.0 (95% CI = 56.0-57.9), 35.4 (95% CI = 34.3-
36.5) and 79.1 (95% CI = 77.5-80.7) per 100,000 popula-
tion, respectively. After adjustment for age, female sex
was associated with a more than doubling of the rate of
paracetamol-related IDO presentations (IRR = 2.21, 95%
CI = 2.13-2.28).
The national rate of IDO presentations to hospital
deceased over the study period (Figure 1). The rate was
212.3 per 100,000 in 2003 and fell annually by 6.7%
(95% CI = 5.8-7.6%) to 173.6 in 2006. Between 2007 and
2008, the rate increased from 175.3 to 187.2 per
100,000, an increase of 7.0% (95% CI = 3.8-10.3%) after
adjustment for age. This trend was also evident for IDO
presentations involving a paracetamol-containing drug.
The rate was 64.3 per 100,000 in 2003 and also fell
annually by 6.7% (95% CI = 5.1-8.3%) to 51.9 in 2006.
Between 2007 and 2008, the rate increased from 51.2 to
55.1 per 100,000, an increase of 6.5% (95% CI = 0.6-
12.6%) after adjustment for age.
Sales to retail pharmacies of distalgesic, other pre-
scription compound analgesics, solpadeine and other
paracetamol-containing drugs increased 4-6% per year
over the eight years (1998-2005) before distalgesic was
withdrawn from the Irish market 2. In 2005, approxi-
mately 40 million tablets of distalgesic were sold to
pharmacies. This fell to 500,000 in 2006, to approxi-
mately 2,000 in 2007 and to none in 2008. Between
2005 and 2006, there was a 48% jump in sales of the
other prescription compound analgesics, an 11%
increase in sales of solpadeine and a 22% increase in
sales of other paracetamol-containing medicines.
Of the 42,849 recorded IDO presentations, distalgesic
was one of the drugs taken in 1,312 (3.1%) acts
(Table 1). The involvement of distalgesic in IDO acts
varied by sex (Chi-square = 12.13, df = 1, p < 0.001),
age (Chi-square = 37.64, df = 4, p < 0.001) and year
(Chi-square = 635.38, df = 5, p < 0.001). Distalgesic was
more common in female IDO acts and was less
Figure 1 National rate of intentional drug overdose presentations (all and those involving a paracetamol-containing drug) to hospital
in Ireland, 2003-2008. Note: Error bars represent the 95% confidence intervals for the rates.
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common with increasing age. In the three years pre-
withdrawal, it was involved in almost 400 presentations
annually, approximately 5% of all IDO presentations.
The three years post-withdrawal saw sharp reductions in
the numbers and proportions of IDO presentations
involving distalgesic (Table 1). A similar pattern was
observed when distalgesic was considered as a propor-
tion of all paracetamol-related IDO presentations. The
drug was involved in 16% of paracetamol-related acts in
2003-2005 but this declined sharply in line with the dis-
talgesic withdrawal (Table 1).
The age-standardised rate of IDO presentations to
hospital involving distalgesic was 10 per 100,000 in
2003-2005 (Figure 3). The rate fell in each of the three
post-withdrawal years - to 2.7 (95% CI = 2.2-3.2) per
100,000 in 2006, 1.6 (95% CI = 1.2-2.0) per 100,000 in
Figure 2 Trends in sales to retail pharmacies in Ireland of paracetamol-containing medicines, 1998-2008.
Table 1 Intentional drug overdose presentations to hospital in Ireland involving distalgesic
n % of all IDO presentations % of paracetamol-related IDO presentations
Sex Male 448 2.7% 10.9%
Female 864 3.3% 9.7%
Age <15 years 42 4.7% 9.5%
15-24 years 488 3.6% 8.9%
25-44 years 556 2.8% 10.6%
45-64 years 213 2.7% 12.4%
65 years+ 13 1.6% 8.3%
Year 2003 386 5.0% 16.2%
2004 356 4.9% 15.7%
2005 371 5.3% 16.5%
2006 109 1.6% 5.5%
2007 64 0.9% 3.2%
2008 26 0.4% 1.2%
Total 1312 3.1% 10.0%
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2007 and 0.6 (95% CI = 0.4-0.9) per 100,000 in 2008. In
contrast, the rate of IDO presentations involving the
other prescription compound analgesics was approxi-
mately 4 per 100,000 in 2003-2005, rising to 5.0 (95%
CI = 4.3-5.7), 6.4 (95% CI = 5.6-7.2) and 6.4 (95% CI =
5.6-7.1) per 100,000 in 2006, 2007 and 2008, respec-
tively. There was no trend evident in the rate of IDO
presentations involving solpadeine.
The rate of IDO presentations to hospital involving dis-
talgesic in 2006-2008 was 83.5% lower than what it had
been in the three years before it was withdrawn (Table
2). This decrease was graded across the three years. Com-
pared to 2003-2005, the rate of distalgesic-related IDO
presentations was 72.3% (95% CI = 66.7-76.9%) lower in
2006, 84.0% (95% CI = 79.8-87.3%) lower in 2007 and
93.8% (95% CI = 91.0-95.7%) lower in 2008. The rate of
IDO presentations involving the other prescription com-
pound analgesics was 43.5% higher in 2006-2008 than in
2003-2005. The increase were somewhat graded - 22.0%
(95% CI = 4.4-42.5%) higher in 2006, 54.5% (95% CI =
34.0-78.3%) higher in 2007 and 53.3% (95% CI = 33.0-
76.7%) higher in 2008. The overall rate of presentations
involving any paracetamol-containing drug was 16.4%
lower in 2006-2008 than in 2003-2005.
The median number of distalgesic tablets taken in
IDO presentations involving the drug was 20 (Interquar-
tlie (IQ) range = 10-30), with men, on average, taking
more distalgesic tablets in IDO acts than women
(Mann-Whitney U = 117,207, p < 0.001; Male median
(IQ range) = 20 (12-36); Female median (IQ range) = 18
Figure 3 National rate of intentional drug overdose presentations to hospital in Ireland involving distalgesic, other prescription
compound analgesics and solpadeine, 2003-2008. Note: Error bars represent the 95% confidence intervals for the rates.
Table 2 Use of analgesics in intentional drug overdose presentations to hospital in Ireland before and after the
withdrawal of distalgesic
Drug involved in presentations 2003-51 2006-81 Change1 Relative change2 (95% CI)2
Distalgesic 10.0 1.6 -8.4 -83.5%3 (-85.7, -81.0%)
Other prescription compound analgesics 4.2 5.9 +1.7 +43.5%3 (+28.6, +60.1%)
Solpadeine 6.3 6.5 +0.2 +2.6% (-6.7, +12.8%)
Any paracetamol 61.3 51.5 -9.8 -16.4%3 (-19.0, -13.7%)
1 Age-standardised rate per 100,000
2 Based on the incidence rate ratio after adjustment for age
3 p < 0.001
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(10-28)). It can be seen from Figure 4 that the number
of distalgesic tablets taken in IDO presentations was
relatively constant in 2003-2006 and decreased slightly
in 2007 and 2008. However, the yearly variation in the
number of distalgesic tablets taken was not statistically
significant (Kruskal-Wallis test chi-square = 4.91, df = 5,
p = 0.427).
Discussion
The withdrawal of distalgesic from the Irish market in
January 2006 resulted in an immediate reduction in
sales to retail pharmacies. The rate of intentional drug
overdose (IDO) presentations to hospital involving dis-
talgesic in 2006-2008 was 84% lower than in the three
years pre-withdrawal. The magnitude of the impact of
the withdrawal was greater than the effects of the with-
drawal of distalgesic (co-proxamol) on drug-related
suicide mortality in Scotland [7] and in England and
Wales [5] where the withdrawal was phased over the
three years 2005-2007. Scottish poisoning deaths invol-
ving co-proxamol as the sole agent were 50% lower in
2005-2006 than in 2000-2004 [7]. In England and
Wales, the three withdrawal years saw a decrease of 59%
in the prescribing of co-proxamol and a 62% decrease in
suicide deaths compared to 1998-2004 [5]. In Sweden,
restrictions on the prescribing of drugs containing dex-
tropropoxyphene were implemented in 2000-2002 and
these were associated with a 66% decrease in sales, a
62% decrease in the number of dextropropoxyphene
poisoning deaths and a 28% decrease in the number of
dextropropoxyphene inquiries to the Swedish Poisons
Information Centre [6].
In Ireland, the 48% jump in sales of the other pre-
scription compound analgesics (Kapake, Paramol, Solpa-
dol, Syndol and Tylex) between 2005 and 2006 was
likely to have been due to doctors prescribing these
drugs as alternatives to the withdrawn distalgesic. The
11% increase in sales of solpadeine and 22% increase in
sales of other paracetamol-containing medicines may
have been partially related to the withdrawal of distalge-
sic. However, these increases were not greatly out of
line with the annual increases in the sales of these drugs
in the years before distalgesic was withdrawn. There was
also evidence of a degree of substitution in respect of
IDO presentations to hospital. The increased availability
of the other prescription compound analgesics resulted
in a significant increase in the rate of IDO presentations
to hospital involving these drugs. However, the magni-
tude of the decrease in distalgesic-related IDO presenta-
tions was about five times greater than the magnitude of
Figure 4 Median number of distalgesic tablets taken in intentional drug overdose presentations to hospital in Ireland, 2003-2008.
Note: Error bars represent the interquartile range.
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the increase in IDO presentations involving the other
prescription compound analgesics. Recent UK studies of
the impact of distalgesic (co-proxamol) withdrawal on
suicide mortality found little or no evidence of substitu-
tion [5,7]. The total rate of IDO presentations to hospi-
tal and the rate of paracetamol-related presentations
were decreasing in the three years before the withdrawal
of distalgesic and continued to do so until 2008.
We found evidence of a time lag in the effect of the
withdrawal of distalgesic on IDO presentations. Sales of
the drug to retail pharmacies decreased by 99% in 2006
whereas the rate of distalgesic-related IDO presentations
was 72%, 84% and 94% lower in 2006, 2007 and 2008,
respectively. The evidence of a reduction in the number
of distalgesic tablets taken in overdose acts was very
limited and only seemed apparent in 2008 and even
then half of those presentations involved more than 15
tablets. These findings may reflect the availability of dis-
talgesic from already-filled prescriptions and a gradual
reduction in household stocks. The Dispose of Unused
Medicines Properly (DUMP) campaign is a separate
initiative also aimed at restricting access to means of
suicidal behaviour http://www.imt.ie/opinion/2009/05/
dumping_drugs_saves_lives.html. Carried out in a num-
ber of areas across Ireland, the DUMP campaign called
on the general public to bring medicines that were out-
of-date or no longer in use to participating pharmacies
where they were collected and subsequently destroyed.
The campaign may have accelerated the disposal of dis-
talgesic from the homes of patients. However, it may
have more effective had the DUMP campaign been
adopted nationally and promoted in conjunction with
the withdrawal of distalgesic. In relation to future pre-
ventive initiatives, there is a need for greater awareness
and promotion of existing initiatives that have the
potential to be complimentary.
The study had a number of strengths and limitations.
We were able to examine data relating to IDO presenta-
tions to the vast majority, though not all, of the hospi-
tals in Ireland. In line with recommendations for the
evaluation of initiatives restricting access to means of
suicidal behaviour [12], we examined data from the
three years before and the three years after the withdra-
wal of distalgesic. We examined sales to retail pharmacy
data to assess changes in the availability of the relevant
drugs. However, we did not include sales to hospital
pharmacies and therefore our figures underestimate
total sales somewhat. Changes in presentation rates and
the number of tablets taken were examined for IDO
presentations involving distalgesic and other relevant
drugs. Substitution to other methods of self-poisoning
or self harm was not examined. Legislation restricting
pack-sizes of paracetamol-only drugs was implemented
during the study period [13] which may explain the
decrease in the rate of paracetamol-related IDO presen-
tations observed in the study period. The study was con-
fined to IDO presentations to hospital emergency
departments and therefore excluded untreated acts and
those managed by general practitioners. It would also
have been of interest to have examined suicide data.
However, at the time of the study, Irish suicide data
were available only up to 2006 and the data could not
distinguish deaths involving distalgesic from those invol-
ving other analgesics.
Conclusions
The withdrawal of distalgesic from the Irish market
resulted in a marked reduction in the rate of IDO pre-
sentations to hospital involving the drug. The smaller
increase in IDO presentations involving other prescrip-
tion compound analgesics constituted evidence of some
substitution. However, the withdrawal of distalgesic in
Ireland can be considered a positive measure in the pre-
vention of non-fatal suicidal behaviour, which is likely
also to have an effect on suicide.
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